230617-66-0

Basic information

• Product Name: 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine
• Synonyms: 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine;2-CHLORO-5-(1-PYRROLIDINYLMETHYL)-PYRIDINE;2-chloro-5-(1-pyrrolidinylmethyl)pyridine(SALTDATA: FREE);Pyridine, 2-chloro-5-(1-pyrrolidinylmethyl)-
• CAS NO: 230617-66-0
• Molecular Formula: C10H13ClN2
• Molecular Weight: 196.68
• Mol File: 230617-66-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine(230617-66-0)
• EPA Substance Registry System: 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine(230617-66-0)

Safety Data

• Hazardous Substances Data: 230617-66-0(Hazardous Substances Data)

Usage

Description

2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine is a chlorinated pyridine derivative with the molecular formula C11H14ClN2. It features a pyrrolidine group attached to the fifth position of the pyridine ring, which contributes to its unique structure and properties. This chemical compound has garnered interest in the field of medicinal chemistry due to its potential therapeutic uses and is a subject of research for the development of new drugs.

Uses

Used in Pharmaceutical Applications:
2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine is utilized as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to serve as a building block for the development of new drugs, particularly those targeting specific biological pathways or receptors.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine is employed as a subject of study to explore its potential therapeutic applications. Its synthesis and characterization are crucial for understanding its properties and how it can be harnessed for the creation of effective and novel pharmaceutical agents.
Used in Drug Development:
2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine is used as a starting material in drug development processes. Its chemical properties and structural features make it a promising candidate for the design and synthesis of innovative therapeutic agents that can address unmet medical needs or improve upon existing treatments.

Upstream product

• 123-75-1 pyrrolidine 
• 70258-18-3 2-chloro-5-(chloromethyl)pyridine 
• 23100-12-1 6-chloronicotinylaldehyde 

Relevant articles and documents

HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS

Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes.

Substituted pyridines as modulators of the mammalian neuronal nicotinic acetylcholine receptor

Novel compounds are provided that modulate the neuronal nicotinic acetylcholine receptor (nAChR), particularly the mammalian nAChR (m-nAChR). The compounds are substituted pyridine derivatives such as analogs of 1-[(6-chloro-3-pyridinyl)methyl]-2-imidazolidine and 1-[(6-chloro-3-pyridinyl)methyl]-2-iminothiazole. Methods of using the novel m-nAChR modulators are also provided, including methods of using the compounds as m-nAChR probes and as therapeutic agents to treat mammalian individuals suffering from conditions, disorders or diseases that are responsive to administration of an m-nAChR modulator. The compounds are useful in treating (1) CNS disorders such as Alzheimer's disease, AIDS-associated dementia, Tourette's Syndrome, attention deficit disorder, and attention deficit disorder, (2) inflammation and inflammatory diseases, (3) conditions caused by or associated with smooth muscle contractions, and (4) withdrawal symptoms associated with cessation of chemical substance abuse. The compounds are also useful as non-opiate analgesics, to treat mild, moderate or severe pain. Pharmaceutical formulations containing an m-nAChR modulator of the invention are provided as well.